Esco Lifesciences Group announced that Esco Aster has officially signed a Memorandum of Understanding (MOU) with Creative Life Science. This collaboration brings together Esco Aster’s deep expertise in Bioreactor × Media Integration, bioprocess standardization, and clinical manufacturing platforms with Creative Life Science’s localized ecosystem in Taiwan’s regenerative medicine industry. Together, the two companies aim to advance Taiwan’s cell therapy and regenerative medicine manufacturing toward global standards.

Esco Aster: Advancing Taiwan’s Global Progress with Clinical-Grade Manufacturing
In recent years, Esco Aster has focused on driving the maturity of cell and biologics processes from RUO (Research Use Only) to GMP (Clinical/Commercial). Through this partnership, we will introduce our Bioreactor × Media Integration technology into the Taiwan market to enhance scalability, production consistency, and quality control for regenerative medicine products—supporting Taiwan’s rapid alignment with international regulatory requirements.

Esco Aster’s key strengths include:

• An integrated bioreactor platform providing controllability and reproducibility for clinical-grade cell manufacturing.

• GMP-grade media and process development capabilities.

• A global technology transfer model supporting customers in building localized manufacturing capacity.

• With these technologies, Esco will support Taiwan in establishing internationally aligned cell manufacturing environments while reducing risks and costs from R&D to large-scale production.

Jointly Advancing a Complete “RUO-to-GMP Transformation” Manufacturing Framework
Creative Life Science’s proposed “RUO-to-GMP Transformation” workflow is highly aligned with Esco Aster’s commitment to standardized cell processing. The collaboration will focus on:

• Establishing scalable process platforms from R&D through clinical stages.

• Implementing Esco Aster’s Bioreactor × Media Integration as the core of cell processing.

• Building internationally compliant GMP cell manufacturing capabilities in Taiwan.

• Supporting companies and medical institutions with CMC development, process validation, and technology transfer.

• Creating a regenerative medicine manufacturing centre capable of serving global clients.

This partnership will substantially enhance Taiwan’s manufacturing competitiveness and accelerate the progression of local biotech companies and therapy developers into clinical stages.

About Esco Aster
Esco Aster is a contract research, development, and manufacturing organization (CRDMO) founded by scientists to enable the translation of bench work into diagnostics, medicines, therapies, cosmeceuticals, and cellular agriculture at affordable prices. Through best-in-class continuous manufacturing platforms, Esco Aster delivers scalable and reliable outcomes. Learn more at www.escoaster.com.

About Creative Life Science Co., Ltd.
Creative Life Science Co., Ltd. is a Taiwan-based biotechnology company dedicated to advancing regenerative medicine and cell therapy innovation. With a strong foundation in localized bioprocess development, clinical translation, and industry–academic collaboration, Creative Life Science provides integrated solutions that support the full spectrum of regenerative medicine—from research and early development to GMP-compliant manufacturing. Learn more at https://www.cmp-micro.com/en/